top of page

Promising New AMD Treatment Faricimab

A new drug to treat Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) has recently demonstrated promising phase III results. The new drug, Faricimab, is a bispecific antibody designed for the eye and is the first of its kind. Current AMD treatment targets the VEGF pathway (Figure 1) and demonstrates a significant reduction in vision loss for neovascular AMD and DME patients. However, frequent injections are needed to accomplish this.

Faricimab works by targeting two pathways-- angiopoietin-2 (ANG-2) and VEGF-A, which drive many retinal conditions. It stabilizes blood vessels within the retina, which in turn, decreases inflammation and leakage. By targeting both pathways, the stabilization of the blood vessels is proposed to last longer than if only one pathway was targeted. The four phase III trials indicate that patients were able to extend treatment times from 4 months out of the last injection. To learn more about the study results, click here.

Figure 1. shows how current anti-VEGF

treatment blocks receptors from binding,

therefore, stabilizing the blood vessels.

29 views0 comments

Recent Posts

See All

Computers, Digital Devices and Eye Strain

You may have heard somewhere that looking at a computer, smartphone or other digital screen for long periods of time will permanently damage your eyes. Thankfully, this is like the old adage about “ru

Vitamins for AMD

People who have a certain form of age-related macular degeneration (AMD) may benefit from a specific mix of vitamins and minerals. Taking these nutritional supplements might help slow this eye disease


bottom of page